Dual-targeting of aberrant glucose metabolism in glioblastoma by Han Shen et al.
Shen et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:14 
DOI 10.1186/s13046-015-0130-0RESEARCH ARTICLE Open AccessDual-targeting of aberrant glucose metabolism in
glioblastoma
Han Shen1, Stephanie Decollogne2, Pierre J Dilda2, Eric Hau1,3, Sylvia A Chung1, Peter P Luk2, Philip J Hogg2
and Kerrie L McDonald1*Abstract
Background: Glioblastoma (GBM) is the most common and malignant primary brain tumor. In contrast to some
other tumor types, aberrant glucose metabolism is an important component of GBM growth and chemoresistance.
Recent studies of human orthotopic GBM in mice and in situ demonstrated GBM cells rely on both glycolysis and
mitochondrial oxidation for glucose catabolism. These observations suggest that the homeostasis of energy
metabolism of GBM cells might be further disturbed by dual-inhibition of glucose metabolism. The present study
aimed to evaluate the efficacy and the mechanisms of dual-targeting therapy in GBM cells.
Methods: Representative GBM cells (immortalized GBM cell lines and patient-derived GBM cells) and non-cancerous
cells were treated with 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO), an in-house designed novel
arsenic-based mitochondrial toxin, in combination with dichloroacetate (DCA), a pyruvate dehydrogenase kinase
inhibitor. The efficacy of this combinatorial therapy was evaluated by MTS assay, clonogenic surviving assay and
apoptotic assays. The underlying mechanisms of this dual-targeting treatment were unraveled by using mitochondrial
membrane potential measurements, cytosol/mitochondrial ROS detection, western blotting, extracellular flux assay and
mass spectrometry.
Results: As monotherapies, both PENAO and DCA induced proliferation arrest in a panel of GBM cell lines and primary
isolates. PENAO inhibited oxygen consumption, induced oxidative stress and depolarized mitochondrial membrane
potential, which in turn activated mitochondria-mediated apoptosis. By combining DCA with PENAO, the two drugs
worked synergistically to inhibit cell proliferation (but had no significant effect on non-cancerous cells), impair the
clonogenicity, and induce mitochondria-mediated apoptosis. An oxidative stress of mitochondrial origin takes a prominent
place in the mechanism by which the combination of PENAO and DCA induces cell death. Additionally, PENAO-induced
oxidative damage was enhanced by DCA through glycolytic inhibition which in turn diminished acid production induced
by PENAO. Moreover, DCA treatment also led to an alteration in the multidrug resistance (MDR) phenotype of GBM cells,
thereby leading to an increased cytosolic accumulation of PENAO.
Conclusions: The findings of this study shed a new light with respect to the dual-targeting of glucose metabolism in
GBM cells and the innovative combination of PENAO and DCA shows promise in expanding GBM therapies.
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Glioblastoma (GBM) is the most common and malig-
nant primary brain tumor in adults [1]. Despite signifi-
cant improvements in the multimodality treatment,
tumor recurrence is inevitable and the overall survival is
dismal with a median survival of only 15 months [1].
New therapeutic strategies and combinations are ur-
gently needed.
Proliferating cancer cells preferentially utilize glycoly-
sis to support growth. This metabolic alteration is com-
monly referred to as the Warburg effect. GBM, like
most cancers, presents this unique metabolic state to
utilize glycolysis for ATP generation [2]. Due to the dis-
parity between the metabolism of cancer and normal
cells, several agents that specifically inhibit glycolysis
have been used as anticancer agents both in vitro and
in vivo [3-5]. Another prominent feature of cancer cells
is their persistent resistance to mitochondria-mediated
apoptosis leading to immortalization [2,6]. Mitochondria
play a central role in ATP production and are also in-
volved in a wide array of cellular processes such as cell
metabolism, proliferation and cell death [7]. Therefore,
targeting tumor mitochondria is a highly attractive anti-
tumor therapeutic strategy [8].
That both glycolysis and mitochondrial oxidative phos-
phorylation (OXPHOS) play key roles in cancer cells has
led to a new research focus into drugs that inhibit both
pathways [7,9,10]. Dichloroacetate (DCA), a pyruvate
dehydrogenase kinase (PDK) inhibitor that reverses the
Warburg effect [11,12], has been demonstrated to inhibit
tumor growth in vivo [11,13,14], and induce apoptosis in
tumors of GBM patients by normalizing the mitochon-
drial activity [15]. In cancer treatment, the mechanism
by which DCA induces apoptosis of cancer cells is via
an enhancement of a flux of electrons through the
electron transport chain (ETC.) resulting in greater
depolarization of the mitochondrial membrane potential
(which is generally hyperpolarized in tumor cells) and
release of cytochrome c followed by subsequent activa-
tion of apoptosis [11]. However, there are some conflict-
ing reports for DCA’s anti-tumor efficacy in vitro and
in vivo [16]. In particular, not all studies found induction
of apoptosis with DCA alone at clinical relevant concen-
trations when tested in vitro [17]. Improved sensitization
of tumor cells to glycolysis inhibition has been achieved
by the combination of glycolytic inhibitors and mito-
chondrial toxins [18,19]. As a glycolytic inhibitor, DCA
has also been reported to be more effective when com-
bined with mitochondria-targeted agents [20,21]. Specif-
ically, DCA has been demonstrated to sensitize cancer
cells towards apoptosis and enhance the effects of sev-
eral anti-cancer agents, including arsenic trioxide [20],
cisplatin [22,23] and metformin [24]. In this way, dual
targeting of glucose metabolism, using DCA to restoresuppressed mitochondrial activity and then an anti-
mitochondrial agent to simultaneously inhibit mitochondrial
function, is a rational strategy to eradicate immortalized
cancer cells by disturbing their bioenergetic metabolism.
4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid
(PENAO) is an in-house designed second generation
arsenic-based mitochondrial toxin that is being tested in a
Phase I dose escalation trial in patients with solid tumors
refractory to standard therapy. PENAO inactivates adenine
nucleotide translocase (ANT), a component of the mito-
chondrial permeability transition pore (MPTP) located in
the inner-mitochondrial membrane, thereby triggering mito-
chondrial apoptotic pathway [25,26]. The trivalent arsenical
moiety of PENAO reacts with ANT, crosslinking Cys57 and
Cys257 of ANT to trigger MPTP opening by increasing the
sensitivity of pore opening to Ca2+ levels [26]. PENAO is
taken up into cells faster and its export by multidrug resist-
ant (MDR) protein 1 and 2 (MRP1/2) is slower compared to
its previous generation, 4-(N-(S-glutathionylacetyl)amino)
phenylarsenoxide (GSAO) [27], enabling it to target
both proliferating tumor and endothelial cells. PENAO
has been demonstrated to inhibit proliferation of a
range of cancer cell lines as well as endothelial cells
in vitro [25], and is also effective in vivo against
subcutaneous human BxPC-3 pancreatic carcinoma
xenografts [25].
The present study examines the anti-tumor activity
and interplay of PENAO and DCA, two metabolism tar-
geting drugs. We demonstrated that DCA enhanced the
cytotoxicity of PENAO to GBM cells through a mechan-
ism involving GSH-mediated redox changes while simul-
taneously offsetting the acid production induced by
PENAO, potentially providing a dual therapeutic
advantage.
Methods
Cell culture and chemicals
GBM cell lines (U87, U251, LN229, DBTRG) and non-
cancerous human lung fibroblast cell line (MRC-5) were
purchased from ATCC. U87, U251 and MRC-5 were
cultured in MEM (Gibco) with 10% fetal bovine serum
(FBS) and 2 mM L-glutamine. LN229 was cultured in
DMEM (Gibco) with 10% FBS and 2 mM L-glutamine.
DBTRG was cultured in RPMI1640 (Gibco) supple-
mented with 10% FBS, 2 mM L-glutamine, 25 mM
HEPES and 1 mM sodium pyruvate. Patient-derived
GBM cell line BAH1 was kindly provided by our collab-
orative researchers at Queensland Institute of Medical
Research and was cultured in Advanced DMEM/F12
(Gibco) mixed with NeurobasalTM-A medium (Gibco)
(1:1) supplemented with B-27 (1×), FGF (20 ng/mL) and
EGF (20 ng/mL). Normal human astrocytes were pur-
chased from Lonza and cultured in Astrocyte Growth
Medium with Astrocyte Medium Bullet Kit (Lonza).
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Sodium dichloroacetate (DCA), N-acetyl-L-cysteine (NAC),
glutathione reduced ethyl ester (GSH-MEE) and buthio-
nine sulphoximine (BSO) were purchased from Sigma-
Aldrich.
Cell proliferation assay
Cells were seeded in 96-well plates followed by treat-
ments with PENAO, DCA, or PENAO-DCA combin-
ation for 72 hr. Cell viability was determined using MTS
assay (Promega) according to the manufacturer’s
instructions.
Cell cycle analysis
Cells were seeded in 6-well plates, followed by treat-
ments as indicated. After treatments, cells were har-
vested and fixed in cold 70% v/v ethanol for at least
2 hr. Fixed cells were washed with phosphate-buffered
saline (PBS) and stained in the dark with a solution con-
taining propidium iodide (PI) (10 μg/mL), Triton X-100
(0.1%) and RNAse (100 μg/mL) for 20 min at room
temperature. DNA content was analyzed using a BD
FACSCanto II flow cytometer and data analysis was per-
formed using FlowJo (TreeStar Inc).
Colony formation assay
Cells were seeded into 6-well plates followed by treat-
ments as indicated. Culture medium was changed after
24 hr treatment. Plates were incubated for 2 weeks un-
disturbed. Colonies were gently washed 2× with PBS
followed by staining and fixation with crystal violet solu-
tion (0.5% in H2O: Methanol 1:1) for 15 min; the crystal
violet solution was removed, and the plates were washed
by immersing in a bucket of cold tap water until the
water ran clear; plates were then inverted on an absorb-
ent pad and allowed to dry overnight. Stained colonies
consisting of >50 cells were counted and the number
was recorded.
Apoptotic assay
Apoptosis was quantified by Annexin-V-FLUOS Staining
Kit (Roche) according to the manufacturer's instructions.
Briefly, cells were seeded in 6-wells plates, followed by
treatments as indicated for 24 hr. Cells were harvested
and stained with a solution containing both Annexin-V
and PI for 30 min, followed by flow cytometry analysis.
As a second confirmation of apoptosis, cleaved Poly
(ADP-ribose) polymerase (c-PARP) was detected by
western blotting.
Mitochondrial membrane potential assay
Cells were plated in 6-well plates as above followed by
treatments as indicated for 16 hr. JC-1 (Sigma; 2 μM)
was added and the cells were allowed to incubate in thestain for 15 min in the dark at 37°C. Cells were then
trypsinized, centrifuged, washed with PBS and resus-
pended in the same buffer (500 μL). JC-1 fluorescence
was measured using flow cytometer.Cytosol/mitochondrial ROS detection
Cells were seeded in 6-well plates, followed by treat-
ments as indicated for 6 hr. Dihydroethidium (DHE)
(Invitrogen) and MitoSOX Red (Invitrogen) were used
to measure the level of cytosol and mitochondrial ROS
production respectively according to the manufacturer’s
instructions. After staining, cells were trypsinized, cen-
trifuged and resuspended in 1 mL PBS (for DHE) or
Hank’s Balanced Salt Solution (HBSS) (for MitoSOX).
Sytox Blue (Invitrogen; 1 μM) was added to counter-
stain for non-viable cells. DHE and MitoSOX Red fluor-
escence was analyzed using flow cytometer.Western blotting
Cells were seeded in 6-well plates, followed by treat-
ments as indicated. Cells were lysed with RIPA buffer
(150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris, pH 8.0), sonicated and
centrifuged (14000 rpm, 10 min, 4°C). Supernatant pro-
tein content was measured using BCA Assay Kit (Pierce,
Rockford, IL, USA). Proteins (50 μg/sample) were sepa-
rated via reducing 10% SDS-PAGE and standard western
blotting procedures [28] were used to detect proteins of
interest with the following primary antibodies: c-PARP
(Cell Signaling Technology, #9541), γ-H2AX (Cell
Signaling Technology, #9718), MRP1 (Enzo Life Sciences,
#106-80107), β-actin (Abcam, ab8227).Detection of cytosolic PENAO accumulation
Cells were seeded in 6-well plates at a density of 7.5 × 105
cells (U87) or 1 × 106 cells (BAH1) per well and allowed
to attach for 24 hr, The cells were treated with 50 μM
PENAO for 4 hr at 37°C, 5% CO2. When indicated,
before the addition of PENAO the cells were pre-treated
with 20 mM DCA for 24 hr. After 4 hr of contact with
PENAO, the culture medium was removed and the cells
were washed twice with ice-cold PBS (5 ml each time).
Cells were left for drying overnight and then lysed with
1 ml of 70% w/w nitric acid. Lysates were diluted 50-fold
and analyzed for arsenic atoms using an Elan 6100 Induct-
ively Coupled Plasma Spectrometer (PerkinElmer Sciex
Instruments). An identical plate was set up in the same ex-
perimental setting for protein extraction. Protein concen-
tration was measured using the Pierce BCA Protein Assay,
and the arsenical level was normalized to protein content
of the samples.
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Cells were seeded in Matrigel-coated XF24 Seahorse
Bioscience cell culture plates at 3 × 104 cells (U87) or
5× 104 cells (BAH1) cells per well in culture media for
24 hr, followed by treatment with indicated drug con-
centrations for another 24 hr. After 48 hr, cell medium
was changed to unbuffered DMEM containing the
same treatment as the previous 24 hr. After calibra-
tion of the XF24 sensor cartridge, the cell plate was
loaded in the analyzer followed by measurements with
oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) over 1 hr. At the end of the
assay, cells were harvested and the numbers of viable
cells were determined by flow cytometry. The mea-
surements of OCR and ECAR were normalized using
the viable cell count.
Statistical analyses
All analyses were performed using GraphPad Prism.
Each independent experiment was performed with at
least triplicate samples per treatment group. Results are
expressed either as mean ± s.d. of replicate values from
three independent experiments or representative of three
independent experiments expressed as means ± s.d. of
replicate measurements. Statistical analysis was per-
formed by two-way analysis of variance corrected by
Dunnet’s test or Student’s t test. All tests of statistical
significance were two-sided and p values < 0.05 were
considered statistically significant.
Results
PENAO in combination with DCA inhibits the growth of
GBM cells in vitro
To examine the effects of PENAO-DCA combination
on GBM cells, we measured cell proliferation and
anchorage-dependent colony formation. Both GBM and
the non-cancerous cell lines were treated with PENAO
and DCA for 72 hr at different concentrations. Inhib-
ition of proliferation was measured and the half-
maximal inhibitory concentrations (IC50) of both drugs
were determined. The IC50 values of PENAO-induced
proliferation arrest were at low micromolar range of
2.5-3.5 μM for all tested GBM cell lines (Figure 1A and
Table 1). In contrast, the IC50 values of DCA were at
suprapharmacological millimolar level (Figure 1B and
Table 1). The IC50 values of PENAO for non-cancerous
cells were 2–3 times higher than that for GBM cells,
whilst the IC50 values of DCA for non-cancerous cells
were not reached (DCA concentration in this study was
tested up to 50 mM) (Figure 1A,B and Table 1). The
combinations of 3.5 μM PENAO and 20 mM DCA
were tested under the same experimental conditions and
cell viability was measured (Figure 1C). The PENAO-
DCA combination further reduced cell viability in allGBM cells compared to each drug alone but had no
significant effect on non-cancerous cells (Figure 1C). To
confirm the effects observed on cell proliferation, we
employed an anchorage-dependent liquid colony culture
for 2 weeks, at the end of which the number of colonies
was quantified. Consistently, either 3.5 μM PENAO or
20 mM DCA reduced the number of colonies in both
DBTRG and LN229 cells (Figure 1D). A significant inhib-
ition of clonogenicity occurred when cells were treated
with PENAO-DCA combination (Figure 1D).
The combination of PENAO and DCA induces G2/M phase
cell cycle arrest
We investigated the PENAO-DCA effect on cell cycle
as a possible cause of the decreased growth rate ob-
served above. U87 cells were treated with 3.5 μM
PENAO and 20 mM DCA for 24 hr, and cell cycle pro-
files were analyzed using flow cytometry. Comparing
with untreated control (15% of cells in G2/M phase),
treating cells with either 3.5 μM PENAO or 20 mM
DCA resulted in a slight but significant (p < 0.05) in-
crease in the proportion of cells (23% and 22% respect-
ively) in the G2/M phase of the cell cycle (Figure 1E).
A combination of both 3.5 μM PENAO and 20 mM
DCA significantly affected (p < 0.01) the cell cycle dy-
namics with 37% cells found in G2/M phase (Figure 1E).
Coinciding with the observed increase in the number
of cells in G2/M arrest, the percentage population of
cells in the S phase significantly decreased (p < 0.05)
from 30% in the untreated to 15% in the combination
treated group (Figure 1E). Similar trend of cell cycle
distribution change in BAH1 cells also occurred after
treated with PENAO, DCA and their combination
(Figure 1E).
DCA enhances the cytotoxicity of PENAO in GBM cells
Further experiments were performed on GBM cells
(U87, DBTRG, LN229 and BAH1) to determine
whether the increased effect of PENAO by DCA was
due to increased induction of apoptosis. Apoptosis
was measured by the Annexin V staining. As a single
drug, 20 mM DCA alone did not induce apoptosis in
all four cell lines; however PENAO was able to induce
apoptosis dose-dependently (Figure 2A,B,C and D).
Furthermore, treating cells with the combination led
to significant increases in the proportion of apoptotic
cells compared to PENAO alone (Figure 2A,B,C, and
D). Apoptotic cell death was further confirmed by the
cleavage of PARP (c-PARP) (Figure 2E) and the
depolarization of mitochondrial membrane potential
(Figure 2F) in the 4 GBM cell lines employed,
indicating that the cytotoxicity of PENAO was en-
hanced by DCA via the mitochondria-mediated apop-
totic pathway.
Figure 1 Combining DCA with PENAO inhibited the growth of GBM cells in vitro. (A) Anti-proliferation effect of PENAO on a panel of GBM
cells and non-cancerous cells after 72 hr treatment. (B) Viable cell number after 72 hr DCA treatment. (C) Viable cell number after 72 hr treatment
of 3.5 μM PENAO, 20 mM DCA and their combination. (D) The clonogenicity of GBM cells (DBTRG and LN229) treated with PENAO, DCA and the
combination. (E) Cell cycle distribution of GBM cells (U87 and BAH1) after 24 hr treatment with PENAO, DCA and PENAO-DCA combination.
Results are presented as means ± s.d. of three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.01 vs PENAO.
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cytotoxicity of PENAO-DCA combination
The mechanisms leading to enhanced apoptosis were
further examined in U87 and BAH1 cells. Increased
oxidative stress contributes to apoptotic cell death.
DCA increases oxidative stress by directing pyruvate
into mitochondria, increasing electron transport chain
activity and thus generating more reactive oxygen spe-
cies (ROS) [15,17,21]. This increased oxidative stress
could potentially sensitize cancer cells towardsTable 1 Cell viabilities of GBM cells and non-cancerous cells a
Compounds IC50 values
GBM cell lines
U87 U251 DBTRG LN2
PENAO (μM) 3.5 ± 0.5 2.5 ± 0.4 3.5 ± 0.2 3.0 ±
DCA (mM) 25.6 ± 6.2 24.3 ± 5.7 28.2 ± 4.5 40.3
The half maximal inhibitory concentration (IC50) values were determined by MTS as
independent experiments, performed in triplicates. Cells were grown as adherent mapoptosis [29]. PENAO has been shown to induces
apoptosis in several cancer cell lines in culture via the
induction of oxidative stress [5,25,26]. We therefore
investigated whether the cytotoxicity of PENAO-DCA
combination was regulated by the change of redox
system. GBM cells (U87 and BAH1) were treated with
5 μM PENAO alone, 20 mM DCA alone and a combin-
ation of PENAO and DCA for 6 hr. Total cellular ROS
levels and mitochondrial superoxide were evaluated by
using DHE and MitoSOX Red, respectively. As singlefter treatments with PENAO, DCA and combination
Non-canerous cell lines
29 BAH1 MRC-5 Normal human astrocytes
0.4 3.4 ± 0.3 8.7 ± 0.7 7.9 ± 1.2
± 5.2 46.5 ± 6.2 n.d. n.d.
say at 72 hr time point for all drug treatments. Values are mean ± s.d. of three
onolayers. n.d. = not determined.
Figure 2 DCA enhanced the cytotoxicity of PENAO in GBM cells. (A, B, C and D) Percentage of apoptotic cells (Annexin V positive) after
24 hr treatment with PENAO (3, 4 and 5 μM), 20 mM DCA, and their combination. (E) The expression of cleaved PARP (c-PARP) in GBM cells
(LN229, DBTRG, U87 and BAH1) after treatments with 5 μM PENAO, 20 mM DCA and their combination. Western blots presented are
representative of 3 independent experiments. (F) The percentage of GBM cells (LN229, DBTRG, U87 and BAH1) with depolarized mitochondria
after 16 hr treatment with PENAO, DCA and the combination. Results are presented as means ± s.d. of three experiments. *p < 0.05, **p < 0.01,
***p < 0.001, #p < 0.01 vs PENAO.
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chondrial and total cellular ROS levels in both U87 and
BAH1 cells. However, the total cellular and mitochon-
drial ROS induced by the combination are significantly
higher than those induced by each single agent (p < 0.01)Figure 3 The oxidative stress plays a prominent role in the cytotoxici
BAH1 cells after 6 hr treatment with 5 μM PENAO, 20 mM DCA and their c
6 hr treatment with PENAO, DCA and combination. (C) Percentage of apop
0.5 mM NAC or +/−0.5 mM GSH-MEE or +/− 0.5 mM BSO. (D) The expressi
PENAO, DCA and PENAO-DCA combination (PENAO and DCA concentrations
experiments. Results are presented as means ± s.d. of three experiments. *p <(Figure 3A,B). Specifically, the combination of PENAO
and DCA resulted in 1.5 ~ 2-fold increases in the fluor-
escence of DHE and 1.7 ~ 2.2-fold increases in MitoSOX
Red fluorescence when compared to untreated control
(Figure 3A,B).ty of PENAO-DCA combination. (A) Cellular ROS levels in U87 and
ombination. (B) Mitochondrial ROS levels in U87 and BAH1 cells after
totic cells (Annexin V positive) after 24 hr PENAO-DCA treatment +/−
on of phosphorylated histone (γ-H2AX) after 24 hr treatment with
as in A). Western blots presented are representative of 3 independent
0.05, **p < 0.01, ***p < 0.001, #p < 0.01 vs PENAO.
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cytotoxicity by the redox system, the antioxidant, NAC, and
an inhibitor of glutathione (GSH) synthesis, BSO, were
employed. Treatment of GBM cells with 0.5 mM NAC
significantly inhibited cell death induced by PENAO-DCA
treatment (p < 0.001) (Figure 3C). To directly confirm
whether reduced GSH played a role in the inhibition of
PENAO-DCA induced cytotoxicity, cell-permeable form of
GSH (GSH-MEE) was employed. Addition of GSH-MEE
also significantly revoked cell death in both U87 and BAH1
cells, compared to those treated with PENAO-DCA com-
bination (p < 0.001) (Figure 3C). In contrast, depletion of
glutathione pool by BSO aggravated the cytotoxicity induced
by PENAO-DCA combination significantly (Figure 3C).
BSO alone (0.5 mM) did not show any effect on GBM cells.
However, combined treatment of PENAO-DCA and
BSO significantly increased the number of apoptotic
cells by 1.3 ~ 2-fold compared to the combination of
PENAO and DCA (Figure 3C). Taken together, these find-
ings indicate GSH-regulated redox change plays a pivotal
role in the cytotoxic effect of PENAO-DCA treatment.
Increased level of superoxide and other ROS can cause
severe damage to cellular macromolecules, especially
DNA. Oxidative damage to DNA can lead to double
strand breaks and phosphorylation of histone (γ-H2AX), a
hallmark of DNA damage [30]. Because the PENAO-DCA
combination induced higher cellular and mitochondrial
levels of ROS than each drug alone, a further experiment
was conducted to investigate the change of γ-H2AX
level after treatment of PENAO and DCA. Consistently,
the co-treatment of PENAO and DCA induced higher
levels of γ-H2AX compared to single treatments
(Figure 3D). These data strongly support that the effect
of PENAO-DCA combination was exerted through the
redox stress.
DCA treatment inhibits MRP1 expression in GBM cells
A recent study reported DCA treatment led to an alter-
ation in the multidrug resistance protein (MDR)Figure 4 DCA treatment inhibits MRP1 expression, thereby increasing
expression of MRP1 in GBM cells (U87 and BAH1 cells) after 24 hr treatmen
independent experiments. (B) Cellular levels of PENAO in U87 and BAH1 ce
presented as means ± s.d. of triplicate measurements. *p < 0.05.phenotype of tumor cells (inhibition of multidrug resist-
ant protein 1, MRP1), thereby enhancing the effective-
ness of cisplatin in a Dalton's lymphoma mouse model
[31]. MRP1 is known to blunt the effect of PENAO by
exporting it from cytosol [25]. Thus we questioned
whether the enhanced cytotoxicity of PENAO by DCA
treatment was due to the inhibition of MRP1 expression
in GBM cells, which in turn increases the accumulation
of PENAO in the cytosol. As expected, western blot
successfully demonstrated that the expression of MRP1
in both U87 and BAH1 cells was down-regulated after
24 hr DCA treatment (Figure 4A). Next, the cytosolic
level of PENAO was determined by mass spectrometry
showing the level of arsenical atom, a surrogate measure
for PENAO levels, accumulated in cytosol. After 24 hr
pre-treatment with 20 mM DCA, the level of PENAO
accumulation was ~1.5-fold higher than that without
DCA pre-treatment (Figure 4B).
DCA promotes oxidative phosphorylation through
inhibiting glycolysis and attenuates PENAO-induced acid
production
To confirm the anti-metabolic effect of PENAO-DCA
combination, two metabolic parameters, oxygen con-
sumption rate (OCR) and extracellular acidification rate
(ECAR), were measured using a Seahorse XF24 analyzer.
PENAO, as a mitochondrial inhibitor, is expected to in-
hibit oxygen consumption whilst stimulate acid produc-
tion. In contrast, DCA is expected to redirect pyruvate
to mitochondrial metabolism at the expense of acidifica-
tion. To examine this, the bioenergetic profiles were ob-
tained under the same experimental conditions following
24 hr PENAO and/or DCA treatments. As shown in
Figure 5A, treatment of U87 cells with 5 μM PENAO re-
sulted in a significant decrease in OCR (p < 0.001) as well
as a substantial increase in ECAR level (p < 0.01) com-
pared to untreated control. In contrast, DCA treatment
led to a slight but significant increase in OCR (p < 0.01)
and a sharp decrease (p < 0.05) in ECAR levels comparedthe cytosolic accumulation of PENAO in GBM cells. (A) The
t with 20 mM DCA. Western blots presented are representative of 3
lls with/without 24 hr pre-treatment with 20 mM DCA. Results are
Figure 5 DCA promotes oxidative phosphorylation through inhibiting glycolysis and attenuates PENAO-induced acid production.
Two metabolic parameters, OCR and ECAR, were measured in (A) U87 cells and (B) BAH1 cells after 24 hr treatment with 5 μM PENAO, 20 mM DCA
and the combination. Results are representative of three independent experiments and presented as means ± s.d. of 3–5 measurements. *p < 0.05,
**p < 0.01, ***p < 0.001, #p < 0.001 vs PENAO.
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bination, the PENAO-induced acid production was largely
eliminated by the addition of DCA (Figure 5A). Similar
metabolic profile of BAH1 cells treated with the PENAO,
DCA and the combination therapy further confirmed
results we observed in U87 cells (Figure 5B).
Discussion
A classic bioenergetic adaptation of cancer cells is the
metabolic shift from OXPHOS to glycolysis regardless of
oxygen availability, a phenomenon termed the Warburg
Effect [2]. The high glycolytic metabolism of GBM
makes it an attractive target of anti-glycolytic therapy.
Although several agents that specifically target glycolysis
have been used as effective anticancer agents in vitro
and in vivo [3-5], this approach has yielded very few
positive results in clinical trials. In particular, recent
studies of human orthotopic gliomas in mice and in situ
demonstrated the Warburg Effect may not necessarily be
the case in brain tumors, where mitochondrial OXPHOS
appears to be more important for the glucose metabol-
ism and chemoresistance [32,33]. Although it is still un-
settled as to whether cancer cells in the brain
preferentially catabolize glucose via aerobic glycolysis or
OXPHOS, it has been proposed that tumor cells can
utilize either glycolysis or OXPHOS due to their plasti-
city of metabolic circuit, particularly when one or the
other pathway is blocked therapeutically [34]. Therefore,
a better therapeutic strategy may arise if dual-blockade
of bioenergetic metabolism is applied.
Previous studies have demonstrated that selective tar-
geting of mitochondrial metabolism of tumor cells syn-
ergistically aggravated cytotoxicity in tumor cells treated
with glycolytic inhibitors [35,36]. Both PENAO and
DCA are currently being evaluated in clinical trials inthe treatment of cancer that target different aspects
of the cancer metabolic phenotype [26,37]. In the cur-
rent study, we demonstrated that PENAO, a novel
mitochondria-targeted agent, is effective at low micro-
molar concentrations against a range of GBM cell lines,
consisting of immortalized and patient-derived GBM cell
lines. The anti-tumor activity of DCA has been shown
in vitro, in vivo, and in a small cohort of GBM patients
[13,15,17,38-40]. However, it has been noticed that there
is a discordance in DCA efficacy when it was tested
in vitro and in vivo [16]. In the present study, the IC50
values of DCA are relatively high (≥20 mM, 72 hr) to
halt the proliferation of GBM cells in culture, which
is consistent with most of the studies in vitro
[13,23,24,39-43]. On the other hand, in vivo studies
testing DCA on pre-clinical rodent models with different
types of malignancy demonstrated encouraging results with
effective doses of 50–200 mg/kg/day [39,40,44], which
translates into approximately 13 kg/kg/day in human
resulting in the serum level of 0.5-1 mM [15,40]. Therefore,
the in vivo achievable concentration (0.5-1 mM) may
not necessarily be correlated with the supraphamacolo-
gical level (5–50 mM) tested in vitro for this anti-
metabolic compound.
When these cells were treated with the combination of
PENAO and DCA, cell proliferation was further inhib-
ited as opposed to each treatment alone. This finding
was also supported by the analysis of cell cycle distribu-
tion showing the significant increase of cell proportions
in the G2/M phase as well as the obvious decreases in
the S phase. As cancer cells are most sensitive to radi-
ation therapy in the G2/M phase of the cell cycle whilst
most resistance in the S phase [45-47], these findings
suggest that PENAO-DCA treatment may have the po-
tential in sensitizing GBM cells to ionizing irradiation.
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failed to induce effective apoptosis, but it enhanced
PENAO-induced apoptosis when co-treatment was admin-
istered. PENAO-DCA combination caused a synergistic
cytotoxicity selectively in GBM cells whilst sparing toxicity
on non-cancerous cells, indicating a therapeutic window be-
tween normal and cancer cells exists. The mode of cytotoxic
action of PENAO is correlated with enhanced mitochondrial
production of ROS, depolarization of mitochondrial mem-
brane potential and inhibition of OXPHOS all leading to
mitochondria-mediated apoptotic cell death [48]. DCA was
combined with PENAO, as we proposed that by reversing
the glycolytic phenotype with DCA and directing more
pyruvate into mitochondrial OXPHOS, simultaneous target-
ing of the mitochondria with PENAO would be more effect-
ive than PENAO alone. Our findings confirmed this
hypothesis by showing that DCA worked synergistically with
PENAO as evidenced from the significant increases in pro-
liferation and G2/M cell cycle arrest, impaired clonogenicity,
ROS production, DNA damage, depolarization of mitochon-
drial membrane potential, and apoptosis compared to each
treatment alone. The general principles of this dual-
targeting strategy are supported by previous literature which
has demonstrated that cells with mitochondrial defects
displayed higher sensitivity to the cytostatic effects of DCA
[10,21,49]. In addition, DCA has been demonstrated to po-
tentiate the anticancer effect of several drugs, such as sulin-
dac, 5-FU and omeprazole, through ROS production, loss of
mitochondrial membrane potential and apoptotic cell death
[43,50,51]. The involvement of ROS in apoptosis mediated
by DCA was demonstrated both by reducing apoptotic cells
with anti-oxidant such as NAC, GSH-MEE and by aug-
menting cell death with glutathione depletion [41,42,50].
These findings were also corroborated in this study by the
fact that the cytotoxicity of PENAO-DCA combination was
clearly regulated by GSH-mediated redox change when
NAC, GSH-MEE and BSO were added. The mode of action
of this combination further suggests it may serve as a potent
chemotherapeutic sensitizer to improve the efficacy of che-
motherapeutic reagents used in the current standard of care,
e.g. temozolomide, by boosting the generation of ROS in
GBM cells.
Interestingly, a recent study reported DCA treatment
led to an inhibition of MRP1 expression, thereby enhan-
cing the effectiveness of cisplatin in a Dalton's lymph-
oma mouse model [31]. MRP1 is known to be well
expressed in GBM cells [52] and to blunt the effect of
PENAO by exporting it out of the cytosol [25]. There-
fore, we examined the expression of MRP1 in GBM cells
after DCA treatment. Consistently, we found pre-
treatment with DCA reduced MRP1 expression in GBM
cells, thereby increasing/retaining the cytosolic level of
PENAO compared to that treated with PENAO alone
(without DCA pre-treatment). This finding revealedanother underlying mechanism of enhanced cytotoxicity
achieved by the combination of PENAO and DCA.
Metabolically, the addition of DCA largely abrogated
PENAO-induced glycolytic rate that would provide can-
cer cells with numerous advantages via the Warburg
effect [53]. In this respect, PENAO-DCA combination
provides a dual therapeutic advantage as DCA enhances
the cytotoxicity of PENAO to GBM cells through a
mechanism involving oxidative stress while simultan-
eously lowering acid production induced by PENAO.
Notably, recent findings have indicated that a metabolic
shift to glycolysis occurred in GBM cells during anti-
angiogenic therapy with bevacizumab, which was
thought to be associated with resistance to anti-
angiogenic therapy and enhanced tumor cell invasion
[54]. Most importantly, thus far there is no effective treat-
ment for recurrent GBM patients who progress following
bevacizumab treatment. Reversal of the bevacizumab-
induced shift in glucose metabolism using DCA has been
shown to effectively inhibit the neoplastic growth of GBM
in vivo [40]. Therefore, adjuvant therapy with drugs target-
ing both glycolytic and mitochondrial glucose metabolism
could be more beneficial in the anti-angiogenic therapy
for GBM.
Conclusions
Our findings provide the first in vitro proof of concept
that dual-targeting of glucose metabolism is an effective
therapeutic approach to eradicate GBM cells. This com-
binatorial strategy halts proliferation, elevates ROS pro-
duction, depolarizes mitochondrial membrane potential,
and induces apoptosis in GBM cells. In addition, DCA in-
hibits the expression of MRP1, which in turn increases the
cytosolic accumulation of PENAO. Moreover, DCA atten-
uates the acid production induced by PENAO treatment
metabolically. Taken together, the findings of this study
warrant further evaluation of this combination in vivo. As
PENAO-DCA combination has the potential to be benefi-
cial in the context of radiotherapy (G2/M arrest) and
temozolomide (ROS production), this dual-targeting
therapy might serve as a novel therapy for GBM.
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